<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31537808</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Src inhibition attenuates polyglutamine-mediated neuromuscular degeneration in spinal and bulbar muscular atrophy.</ArticleTitle><Pagination><StartPage>4262</StartPage><MedlinePgn>4262</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4262</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-019-12282-7</ELocationID><Abstract><AbstractText>Spinal and bulbar muscular atrophy (SBMA) is a neuromuscular disease caused by an expanded CAG repeat in the androgen receptor (AR) gene. Here, we perform a comprehensive analysis of signaling pathways in a mouse model of SBMA (AR-97Q mice) utilizing a phosphoprotein assay. We measure the levels of 17 phosphorylated proteins in spinal cord and skeletal muscle of AR-97Q mice at three stages. The level of phosphorylated Src (p-Src) is markedly increased in the spinal cords and skeletal muscles of AR-97Q mice prior to the onset. Intraperitoneal administration of a Src kinase inhibitor improves the behavioral and histopathological phenotypes of the transgenic mice. We identify p130Cas as an effector molecule of Src and show that the phosphorylated p130Cas is elevated in murine and cellular models of SBMA. These results suggest that Src kinase inhibition is a potential therapy for SBMA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iida</LastName><ForeName>Madoka</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya city, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Japan Society for the Promotion of Science, 5-3-1, Kojimachi, Chiyoda-ku, Tokyo, 102-0083, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahashi</LastName><ForeName>Kentaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya city, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kondo</LastName><ForeName>Naohide</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya city, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakatsuji</LastName><ForeName>Hideaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya city, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tohnai</LastName><ForeName>Genki</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya city, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsutsumi</LastName><ForeName>Yutaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya city, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noda</LastName><ForeName>Seiya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya city, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Suzuka National Hospital, 3-2-1, Kasado, Suzuka city, Mie, 513-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murakami</LastName><ForeName>Ayuka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya city, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Suzuka National Hospital, 3-2-1, Kasado, Suzuka city, Mie, 513-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onodera</LastName><ForeName>Kazunari</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya city, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Aichi Medical University School of Medicine, 1, Karimata, Yazako, Nagakute-city, Aichi, 480-1195, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okada</LastName><ForeName>Yohei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya city, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Aichi Medical University School of Medicine, 1, Karimata, Yazako, Nagakute-city, Aichi, 480-1195, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, 35, Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakatochi</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1838-4837</Identifier><AffiliationInfo><Affiliation>Department of Nursing, Nagoya University Graduate School of Medicine, 1-1-20 Daiko-Minami, Higashi-ku, Nagoya city, Aichi, 461-8673, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsukagoshi Okabe</LastName><ForeName>Yuka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Advanced Medicine, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya city, Aichi, 466-8560, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Shinobu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Advanced Medicine, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya city, Aichi, 466-8560, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizuno</LastName><ForeName>Masaaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Advanced Medicine, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya city, Aichi, 466-8560, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adachi</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9302-4663</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Occupational and Environmental Health School of Medicine, 1-1, Iseigaoka, Yahatanichi-ku, Kitakyushu-city, Fukuoka, 807-0804, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okano</LastName><ForeName>Hideyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, 35, Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobue</LastName><ForeName>Gen</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-4769-5922</Identifier><AffiliationInfo><Affiliation>Brain and Mind Research Center, Nagoya University, 65 Tsurumai-cho, Showa-ku, Nagoya city, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Masahisa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9453-9311</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya city, Aichi, 466-8550, Japan. ka2no@med.nagoya-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000607144">AR protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050719">Crk-Associated Substrate Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="D016392">Proto-Oncogene Proteins pp60(c-src)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="D019061">src-Family Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050719" MajorTopicYN="N">Crk-Associated Substrate Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016392" MajorTopicYN="N">Proto-Oncogene Proteins pp60(c-src)</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019061" MajorTopicYN="N">src-Family Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31537808</ArticleId><ArticleId IdType="pmc">PMC6753158</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-12282-7</ArticleId><ArticleId IdType="pii">10.1038/s41467-019-12282-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology. 1968;18:671&#x2013;680. doi: 10.1212/WNL.18.7.671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.18.7.671</ArticleId><ArticleId IdType="pubmed">4233749</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobue G, et al. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain. 1989;112(Pt 1):209&#x2013;232. doi: 10.1093/brain/112.1.209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/112.1.209</ArticleId><ArticleId IdType="pubmed">2917278</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, et al. Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA) Prog. Neurobiol. 2012;99:246&#x2013;256. doi: 10.1016/j.pneurobio.2012.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2012.05.007</ArticleId><ArticleId IdType="pubmed">22609045</ArticleId></ArticleIdList></Reference><Reference><Citation>Atsuta N, et al. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain. 2006;129:1446&#x2013;1455. doi: 10.1093/brain/awl096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl096</ArticleId><ArticleId IdType="pubmed">16621916</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischbeck KH. Spinal and bulbar muscular atrophy overview. J. Mol. Neurosci. 2016;58:317&#x2013;320. doi: 10.1007/s12031-015-0674-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-015-0674-7</ArticleId><ArticleId IdType="pmc">PMC5094812</ArticleId><ArticleId IdType="pubmed">26547319</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, et al. Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled study. J. Neurol. Neurosurg. Psychiatry. 2017;88:1026&#x2013;1032. doi: 10.1136/jnnp-2017-316015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316015</ArticleId><ArticleId IdType="pubmed">28780536</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:875&#x2013;884. doi: 10.1016/S1474-4422(10)70182-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70182-4</ArticleId><ArticleId IdType="pubmed">20691641</ArticleId></ArticleIdList></Reference><Reference><Citation>Soraru G, et al. Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. J. Neurol. Sci. 2008;264:100&#x2013;105. doi: 10.1016/j.jns.2007.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2007.08.012</ArticleId><ArticleId IdType="pubmed">17854832</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, et al. Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J. Clin. Invest. 2006;116:2663&#x2013;2672. doi: 10.1172/JCI28773..</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI28773.</ArticleId><ArticleId IdType="pmc">PMC1564432</ArticleId><ArticleId IdType="pubmed">16981011</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi C, et al. Insulinlike growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy. Mol. Med. 2012;18:1261&#x2013;1268. doi: 10.2119/molmed.2012.00271.</Citation><ArticleIdList><ArticleId IdType="doi">10.2119/molmed.2012.00271</ArticleId><ArticleId IdType="pmc">PMC3521783</ArticleId><ArticleId IdType="pubmed">22952056</ArticleId></ArticleIdList></Reference><Reference><Citation>Monks DA, et al. Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc. Natl Acad. Sci. USA. 2007;104:18259&#x2013;18264. doi: 10.1073/pnas.0705501104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0705501104</ArticleId><ArticleId IdType="pmc">PMC2084330</ArticleId><ArticleId IdType="pubmed">17984063</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes CJ, et al. Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron. 2014;82:295&#x2013;307. doi: 10.1016/j.neuron.2014.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.03.001</ArticleId><ArticleId IdType="pmc">PMC4096235</ArticleId><ArticleId IdType="pubmed">24742458</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahashi K, et al. Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 2015;24:5985&#x2013;5994. doi: 10.1093/hmg/ddv300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv300</ArticleId><ArticleId IdType="pubmed">26231218</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman AP, et al. Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep. 2014;7:774&#x2013;784. doi: 10.1016/j.celrep.2014.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.02.008</ArticleId><ArticleId IdType="pmc">PMC4356525</ArticleId><ArticleId IdType="pubmed">24746732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijikata Y, et al. Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy. Ann. Clin. Transl. Neurol. 2016;3:537&#x2013;546. doi: 10.1002/acn3.324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.324</ArticleId><ArticleId IdType="pmc">PMC4931718</ArticleId><ArticleId IdType="pubmed">27386502</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell. 1995;80:225&#x2013;236. doi: 10.1016/0092-8674(95)90405-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(95)90405-0</ArticleId><ArticleId IdType="pubmed">7834742</ArticleId></ArticleIdList></Reference><Reference><Citation>Minamiyama M, et al. Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract. Nat. Med. 2012;18:1531&#x2013;1538. doi: 10.1038/nm.2932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2932</ArticleId><ArticleId IdType="pubmed">23023499</ArticleId></ArticleIdList></Reference><Reference><Citation>Iida M, et al. Pioglitazone suppresses neuronal and muscular degeneration caused by polyglutamine-expanded androgen receptors. Hum. Mol. Genet. 2015;24:314&#x2013;329. doi: 10.1093/hmg/ddu445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu445</ArticleId><ArticleId IdType="pubmed">25168383</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorge JD, et al. Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line. PLoS ONE. 2011;6:e19309. doi: 10.1371/journal.pone.0019309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0019309</ArticleId><ArticleId IdType="pmc">PMC3082570</ArticleId><ArticleId IdType="pubmed">21541295</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler DL, Iida M, Dunn EF. The role of Src in solid tumors. Oncologist. 2009;14:667&#x2013;678. doi: 10.1634/theoncologist.2009-0009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2009-0009</ArticleId><ArticleId IdType="pmc">PMC3303596</ArticleId><ArticleId IdType="pubmed">19581523</ArticleId></ArticleIdList></Reference><Reference><Citation>Janostiak R, Pataki AC, Brabek J, Rosel D. Mechanosensors in integrin signaling: the emerging role of p130Cas. Eur. J. Cell Biol. 2014;93:445&#x2013;454. doi: 10.1016/j.ejcb.2014.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcb.2014.07.002</ArticleId><ArticleId IdType="pubmed">25062607</ArticleId></ArticleIdList></Reference><Reference><Citation>Camacho Leal Mdel P, et al. p130Cas/BCAR1 scaffold protein in tissue homeostasis and pathogenesis. Gene. 2015;562:1&#x2013;7. doi: 10.1016/j.gene.2015.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2015.02.027</ArticleId><ArticleId IdType="pmc">PMC6639054</ArticleId><ArticleId IdType="pubmed">25727852</ArticleId></ArticleIdList></Reference><Reference><Citation>Vultur A, et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol. Cancer Ther. 2008;7:1185&#x2013;1194. doi: 10.1158/1535-7163.MCT-08-0126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-08-0126</ArticleId><ArticleId IdType="pmc">PMC2794837</ArticleId><ArticleId IdType="pubmed">18483306</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M, Nada S, Yamanashi Y, Yamamoto T, Nakagawa H. CSK: a protein-tyrosine kinase involved in regulation of src family kinases. J. Biol. Chem. 1991;266:24249&#x2013;24252.</Citation><ArticleIdList><ArticleId IdType="pubmed">1722201</ArticleId></ArticleIdList></Reference><Reference><Citation>Roskoski R., Jr. Src kinase regulation by phosphorylation and dephosphorylation. Biochem. Biophys. Res. Commun. 2005;331:1&#x2013;14. doi: 10.1016/j.bbrc.2005.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2005.03.012</ArticleId><ArticleId IdType="pubmed">15845350</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M. Regulation of the SRC family kinases by Csk. Int J. Biol. Sci. 2012;8:1385&#x2013;1397. doi: 10.7150/ijbs.5141.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.5141</ArticleId><ArticleId IdType="pmc">PMC3492796</ArticleId><ArticleId IdType="pubmed">23139636</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliaccio A, et al. Sex steroid hormones act as growth factors. J. Steroid Biochem. Mol. Biol. 2002;83:31&#x2013;35. doi: 10.1016/S0960-0760(02)00264-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-0760(02)00264-9</ArticleId><ArticleId IdType="pubmed">12650699</ArticleId></ArticleIdList></Reference><Reference><Citation>Shupnik MA. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene. 2004;23:7979&#x2013;7989. doi: 10.1038/sj.onc.1208076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1208076</ArticleId><ArticleId IdType="pubmed">15489915</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliaccio A, et al. Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth. Oncogene. 2007;26:6619&#x2013;6629. doi: 10.1038/sj.onc.1210487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1210487</ArticleId><ArticleId IdType="pubmed">17486077</ArticleId></ArticleIdList></Reference><Reference><Citation>Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene. 2000;19:5636&#x2013;5642. doi: 10.1038/sj.onc.1203912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1203912</ArticleId><ArticleId IdType="pubmed">11114744</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 1991;64:693&#x2013;702. doi: 10.1016/0092-8674(91)90499-O.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(91)90499-O</ArticleId><ArticleId IdType="pubmed">1997203</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik, S. &amp; Cuervo, A. M. The coming of age of chaperone-mediated autophagy. Nat. Rev. Mol. Cell Biol.19, 365&#x2013;381 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6399518</ArticleId><ArticleId IdType="pubmed">29626215</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertsch S, Kramer OH. The interplay between histone deacetylases and rho kinases is important for cancer and neurodegeneration. Cytokine Growth Factor Rev. 2017;37:29&#x2013;45. doi: 10.1016/j.cytogfr.2017.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2017.05.006</ArticleId><ArticleId IdType="pubmed">28606734</ArticleId></ArticleIdList></Reference><Reference><Citation>Culig Z, Hobisch A, Bartsch G, Klocker H. Androgen receptor&#x2013;an update of mechanisms of action in prostate cancer. Urol. Res. 2000;28:211&#x2013;219. doi: 10.1007/s002400000111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002400000111</ArticleId><ArticleId IdType="pubmed">11011957</ArticleId></ArticleIdList></Reference><Reference><Citation>Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat. Rev. Cancer. 2002;2:389&#x2013;396. doi: 10.1038/nrc801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc801</ArticleId><ArticleId IdType="pmc">PMC4124639</ArticleId><ArticleId IdType="pubmed">12044015</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai SJ, Ma AH, Tepper CG, Chen HW, Kung HJ. Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications. Cancer Res. 2006;66:10449&#x2013;10459. doi: 10.1158/0008-5472.CAN-06-2582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-06-2582</ArticleId><ArticleId IdType="pubmed">17079466</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z, et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell. 2006;10:309&#x2013;319. doi: 10.1016/j.ccr.2006.08.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2006.08.021</ArticleId><ArticleId IdType="pubmed">17045208</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliaccio A, et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J. 2000;19:5406&#x2013;5417. doi: 10.1093/emboj/19.20.5406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/19.20.5406</ArticleId><ArticleId IdType="pmc">PMC314017</ArticleId><ArticleId IdType="pubmed">11032808</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarif JC, Lamb LE, Schulz VV, Nollet EA, Miranti CK. Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase. Oncotarget. 2015;6:6862&#x2013;6876. doi: 10.18632/oncotarget.3119.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.3119</ArticleId><ArticleId IdType="pmc">PMC4466655</ArticleId><ArticleId IdType="pubmed">25730905</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr HT. Polyglutamine neurodegeneration: expanded glutamines enhance native functions. Curr. Opin. Genet. Dev. 2012;22:251&#x2013;255. doi: 10.1016/j.gde.2012.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gde.2012.01.001</ArticleId><ArticleId IdType="pmc">PMC3340441</ArticleId><ArticleId IdType="pubmed">22284692</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedelsky NB, et al. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron. 2010;67:936&#x2013;952. doi: 10.1016/j.neuron.2010.08.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.08.034</ArticleId><ArticleId IdType="pmc">PMC3514079</ArticleId><ArticleId IdType="pubmed">20869592</ArticleId></ArticleIdList></Reference><Reference><Citation>Sicheri F, Kuriyan J. Structures of Src-family tyrosine kinases. Curr. Opin. Struct. Biol. 1997;7:777&#x2013;785. doi: 10.1016/S0959-440X(97)80146-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0959-440X(97)80146-7</ArticleId><ArticleId IdType="pubmed">9434895</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 1997;13:513&#x2013;609. doi: 10.1146/annurev.cellbio.13.1.513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.cellbio.13.1.513</ArticleId><ArticleId IdType="pubmed">9442882</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul R, et al. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat. Med. 2001;7:222&#x2013;227. doi: 10.1038/84675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/84675</ArticleId><ArticleId IdType="pubmed">11175854</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna S, Roy S, Park HA, Sen CK. Regulation of c-Src activity in glutamate-induced neurodegeneration. J. Biol. Chem. 2007;282:23482&#x2013;23490. doi: 10.1074/jbc.M611269200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M611269200</ArticleId><ArticleId IdType="pubmed">17569670</ArticleId></ArticleIdList></Reference><Reference><Citation>Um JW, et al. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 2012;15:1227&#x2013;1235. doi: 10.1038/nn.3178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3178</ArticleId><ArticleId IdType="pmc">PMC3431439</ArticleId><ArticleId IdType="pubmed">22820466</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson M, et al. The complex PrP(c)-Fyn couples human oligomeric Abeta with pathological tau changes in Alzheimer&#x2019;s disease. J. Neurosci. 2012;32:16857&#x2013;16871a. doi: 10.1523/JNEUROSCI.1858-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1858-12.2012</ArticleId><ArticleId IdType="pmc">PMC3568961</ArticleId><ArticleId IdType="pubmed">23175838</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman AC, et al. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann. Neurol. 2015;77:953&#x2013;971. doi: 10.1002/ana.24394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24394</ArticleId><ArticleId IdType="pmc">PMC4447598</ArticleId><ArticleId IdType="pubmed">25707991</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura, K., et al. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci. Transl. Med. 9, 391 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28539470</ArticleId></ArticleIdList></Reference><Reference><Citation>Posadas EM, et al. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016;76:286&#x2013;293. doi: 10.1002/pros.23119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pros.23119</ArticleId><ArticleId IdType="pmc">PMC4904773</ArticleId><ArticleId IdType="pubmed">26493492</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy SM, et al. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest. New Drugs. 2015;33:977&#x2013;984. doi: 10.1007/s10637-015-0257-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10637-015-0257-z</ArticleId><ArticleId IdType="pubmed">26062928</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett A, Pellet-Many C, Zachary IC, Evans IM, Frankel P. p130Cas: a key signalling node in health and disease. Cell Signal. 2013;25:766&#x2013;777. doi: 10.1016/j.cellsig.2012.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2012.12.019</ArticleId><ArticleId IdType="pubmed">23277200</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, et al. Transforming growth factor-beta 1-induced apoptosis is blocked by beta 1-integrin-mediated mitogen-activated protein kinase activation in human hepatoma cells. Cancer Sci. 2004;95:878&#x2013;886. doi: 10.1111/j.1349-7006.2004.tb02197.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1349-7006.2004.tb02197.x</ArticleId><ArticleId IdType="pubmed">15546505</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendt MK, Smith JA, Schiemann WP. p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity. J. Biol. Chem. 2009;284:34145&#x2013;34156. doi: 10.1074/jbc.M109.023614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.023614</ArticleId><ArticleId IdType="pmc">PMC2797185</ArticleId><ArticleId IdType="pubmed">19822523</ArticleId></ArticleIdList></Reference><Reference><Citation>Oktay M, Wary KK, Dans M, Birge RB, Giancotti FG. Integrin-mediated activation of focal adhesion kinase is required for signaling to Jun NH2-terminal kinase and progression through the G1 phase of the cell cycle. J. Cell Biol. 1999;145:1461&#x2013;1469. doi: 10.1083/jcb.145.7.1461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.145.7.1461</ArticleId><ArticleId IdType="pmc">PMC2133163</ArticleId><ArticleId IdType="pubmed">10385525</ArticleId></ArticleIdList></Reference><Reference><Citation>Coso OA, et al. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell. 1995;81:1137&#x2013;1146. doi: 10.1016/S0092-8674(05)80018-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(05)80018-2</ArticleId><ArticleId IdType="pubmed">7600581</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, et al. Disrupted transforming growth factor-beta signaling in spinal and bulbar muscular atrophy. J. Neurosci. 2010;30:5702&#x2013;5712. doi: 10.1523/JNEUROSCI.0388-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0388-10.2010</ArticleId><ArticleId IdType="pmc">PMC6632356</ArticleId><ArticleId IdType="pubmed">20410122</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto N, et al. Immortalization of human myogenic progenitor cell clone retaining multipotentiality. Biochem. Biophys. Res. Commun. 2006;348:1383&#x2013;1388. doi: 10.1016/j.bbrc.2006.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.08.006</ArticleId><ArticleId IdType="pubmed">16919240</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiomi K, et al. CDK4 and cyclin D1 allow human myogenic cells to recapture growth property without compromising differentiation potential. Gene Ther. 2011;18:857&#x2013;866. doi: 10.1038/gt.2011.44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2011.44</ArticleId><ArticleId IdType="pubmed">21490680</ArticleId></ArticleIdList></Reference><Reference><Citation>Okita K, et al. A more efficient method to generate integration-free human iPS cells. Nat. Methods. 2011;8:409&#x2013;412. doi: 10.1038/nmeth.1591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1591</ArticleId><ArticleId IdType="pubmed">21460823</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimojo D, et al. Rapid, efficient, and simple motor neuron differentiation from human pluripotent stem cells. Mol. Brain. 2015;8:79. doi: 10.1186/s13041-015-0172-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-015-0172-4</ArticleId><ArticleId IdType="pmc">PMC4666063</ArticleId><ArticleId IdType="pubmed">26626025</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada Y, et al. Spatiotemporal recapitulation of central nervous system development by murine embryonic stem cell-derived neural stem/progenitor cells. Stem Cells. 2008;26:3086&#x2013;3098. doi: 10.1634/stemcells.2008-0293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/stemcells.2008-0293</ArticleId><ArticleId IdType="pubmed">18757299</ArticleId></ArticleIdList></Reference><Reference><Citation>Waza M, et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 2005;11:1088&#x2013;1095. doi: 10.1038/nm1298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1298</ArticleId><ArticleId IdType="pubmed">16155577</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller WE, et al. beta-arrestin1 interacts with the catalytic domain of the tyrosine kinase c-SRC. Role of beta-arrestin1-dependent targeting of c-SRC in receptor endocytosis. J. Biol. Chem. 2000;275:11312&#x2013;11319. doi: 10.1074/jbc.275.15.11312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.275.15.11312</ArticleId><ArticleId IdType="pubmed">10753943</ArticleId></ArticleIdList></Reference><Reference><Citation>Zvara A, et al. Activation of the focal adhesion kinase signaling pathway by structural alterations in the carboxyl-terminal region of c-Crk II. Oncogene. 2001;20:951&#x2013;961. doi: 10.1038/sj.onc.1204173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1204173</ArticleId><ArticleId IdType="pubmed">11314030</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron. 2002;35:843&#x2013;854. doi: 10.1016/S0896-6273(02)00834-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00834-6</ArticleId><ArticleId IdType="pubmed">12372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Adachi H, et al. CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. J. Neurosci. 2007;27:5115&#x2013;5126. doi: 10.1523/JNEUROSCI.1242-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1242-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672370</ArticleId><ArticleId IdType="pubmed">17494697</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo N, et al. Heat shock factor-1 influences pathological lesion distribution of polyglutamine-induced neurodegeneration. Nat. Commun. 2013;4:1405. doi: 10.1038/ncomms2417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2417</ArticleId><ArticleId IdType="pubmed">23360996</ArticleId></ArticleIdList></Reference><Reference><Citation>Iida, M. et al. Src inhibition attenuates polyglutamine-mediated neuromuscular degeneration in spinal and bulbar muscular atrophy. Mendeley, 10.17632/sz4v5tcdyv.2 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6753158</ArticleId><ArticleId IdType="pubmed">31537808</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>